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Purpose of the study
Liver fibrosis (LF) progression is fated to become one of
the major long-term complications in HIV patients,
even in those without HCV or HBV co-infections (HIV-
mono-infected). The aim of this study was to assess LF
progression in HIV-mono-infected patients and asso-
ciated risk factors.
Methods
Observational retrospective study. All HIV naive patients
who started HAART from 1996 to 2006 were included.
Concordance between FIB-4 and APRI scores was assessed
using the weighted kappa coefficient. Rates of transition
from lower classes to higher classes were estimated by
Kaplan-Meier analysis. Cox regression models were
applied to assess possible predictors both at baseline and
during the follow-up.
Summary of results
1,112 naive patients were selected. A moderate concor-
dance between FIB-4 and APRI was demonstrated
(K=0.573). For FIB-4, the incidence of transition to higher
classes was 0.064 PYFU (95% CI, 0.056-0.072), while for
APRI the incidence of transition was 0.099 PYFU (95% CI,
0.089-0.110). Viro-immunological control during HIV
infection appeared to reduce the risk of both FIB-4 and
APRI transitions. HIV-RNA <500 copies/ml (for FIB-4:
HR 2.456 p<0.0001; for APRI: HR 2.084 p<0.0001) and
higher CD4 T-cell counts only for FIB-4 (HR 0.881
p=0.0004 for 100 cells higher) during the follow-up were
statistically protective. Among baseline variables, for FIB-4
transition, age ≥ 40 years (HR 1.037 p<0.0001) and higher
FIB-4 values (HR 1.526 p=0.0038) were associated with
increased risk of LF progression, while sexual risk factor
for HIV acquisition resulted to be protective (HR 0.524
p=0.0314). For APRI, male gender (HR 1.390 p=0.017),
higher GGT values (HR 1.015 p=0.014) and higher APRI
values (HR 1.748 p=0.007) were independently associated
with APRI transition. A sensitivity analysis demonstrated
that DDX drugs (stavudine, didanosine, zalcitabine)as
time-dependent covariates were associated with a signifi-
cant risk of transition with FIB-4 (HR 1.662 p=0.0007) or
APRI (HR 1.661 p=0.0001).
Conclusions
Our data suggest that a better viro-immunological con-
trol of HIV infection may slow down fibrosis progres-
sion provided that DDX are avoided. Moreover our
analysis provided a comprehensive feature of the risk
factors that should be controlled in clinical practice.
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